Invention Grant
- Patent Title: Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
-
Application No.: US15903662Application Date: 2018-02-23
-
Publication No.: US10765670B2Publication Date: 2020-09-08
- Inventor: Franck Mouthon , Mathieu Charveriat
- Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
- Applicant Address: FR Paris
- Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
- Current Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
- Current Assignee Address: FR Paris
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@4daa461c
- Main IPC: A61K31/445
- IPC: A61K31/445 ; A61P25/28 ; A61K31/49 ; A61K45/06 ; A61K31/196 ; A61K31/19
Abstract:
This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.
Public/Granted literature
- US20180177773A1 USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS Public/Granted day:2018-06-28
Information query
IPC分类:
